<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04934397</url>
  </required_header>
  <id_info>
    <org_study_id>AL42</org_study_id>
    <nct_id>NCT04934397</nct_id>
  </id_info>
  <brief_title>Term Infants Fed a Partially Hydrolyzed Whey Protein-Based Formula</brief_title>
  <official_title>Tolerance in Term Infants Fed a Partially Hydrolyzed Whey Protein-Based Formula With Oligosaccharides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effects of partially hydrolyzed whey protein-based infant formula with&#xD;
      oligosaccharides on symptoms of formula intolerance in healthy, term infants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fussiness</measure>
    <time_frame>Baseline to Study Day (SDAY) 2</time_frame>
    <description>Absolute and % change in fussiness severity reported from Daily Tolerance Diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Tolerance</measure>
    <time_frame>Baseline to SDAY 28</time_frame>
    <description>Parent Completed Diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool</measure>
    <time_frame>Baseline to SDAY 28</time_frame>
    <description>Parent Completed Diary</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Formula Intake</measure>
    <time_frame>SDAY 1 to SDAY 28</time_frame>
    <description>Parent Completed Diary</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>SDAY 1 to SDAY 28</time_frame>
    <description>Weight in grams</description>
  </other_outcome>
  <other_outcome>
    <measure>Length</measure>
    <time_frame>SDAY 1 to SDAY 28</time_frame>
    <description>Length in cm</description>
  </other_outcome>
  <other_outcome>
    <measure>Infant Feeding and Stool Patterns Questionnaire</measure>
    <time_frame>SDAY 1 to SDAY 28</time_frame>
    <description>Parent completed questionnaire; 16, 5-point Likert scale questions, scaled from 1) Always to 5) Never</description>
  </other_outcome>
  <other_outcome>
    <measure>Formula Satisfaction Questionnaire</measure>
    <time_frame>SDAY 1 to SDAY 28</time_frame>
    <description>Parent completed questionnaire; 13 questions of up to 5 categories scaled from positive to negative</description>
  </other_outcome>
  <other_outcome>
    <measure>Parental Perspectives</measure>
    <time_frame>SDAY 1 to SDAY 28</time_frame>
    <description>Parent completed questionnaire; 4, 5-point Likert scale questions, scaled from negative to positive</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Resource Utilization</measure>
    <time_frame>SDAY 1 to SDAY 28</time_frame>
    <description>Number of Visits</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>SDAY 1 to SDAY 28</time_frame>
    <description>Parent reported adverse events</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Gastro-Intestinal Tolerance</condition>
  <arm_group>
    <arm_group_label>Study Infant Formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Feed ad libitum during study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Study Infant Formula</intervention_name>
    <description>Powdered partially hydrolyzed whey (WPH) based infant formula with oligosaccharides</description>
    <arm_group_label>Study Infant Formula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is judged to be in good health as determined from participant's medical&#xD;
             history by parent report&#xD;
&#xD;
          -  Participant is a singleton from a full-term birth with a gestational age of 37-42&#xD;
             weeks&#xD;
&#xD;
          -  Participant's birth weight was &gt;= 2490 g (~5 lbs. 8 oz.)&#xD;
&#xD;
          -  Participant is identified by parents as very fussy or extremely fussy on current&#xD;
             formula in the Baseline Tolerance Evaluation&#xD;
&#xD;
          -  Participant is exclusively formula-fed at time of study entry and Parent(s) confirm&#xD;
             their intention to feed their infant the study product as the sole source of nutrition&#xD;
             for the duration of the study, unless instructed otherwise by their healthcare&#xD;
             professional&#xD;
&#xD;
          -  Parent(s) of participants confirm their intention not to administer vitamin, mineral,&#xD;
             human milk oligosaccharides (HMO), prebiotic(s), or probiotic(s) supplements (with the&#xD;
             exception of vitamin D supplements if instructed by their healthcare professional),&#xD;
             non-study formula, foods, juices, or other sources of nutrition to their infant from&#xD;
             enrollment through the duration of the study&#xD;
&#xD;
          -  Participant's parent(s) has voluntarily signed and dated an Informed Consent Form&#xD;
             (ICF), approved by an Institutional Review Board/Independent Ethics Committee&#xD;
             (IRB/IEC) and provided Health Insurance Portability and Accountability Act (HIPAA) (or&#xD;
             other applicable privacy regulation) authorization prior to any participation in the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  An adverse maternal, fetal, or participant medical history that is thought by the&#xD;
             investigator to have potential for effects on tolerance, growth, and/or development.&#xD;
             This includes but is not limited to suspected maternal substance abuse.&#xD;
&#xD;
          -  Participant is taking and plans to continue taking medications (including OTC, such as&#xD;
             MyliconÂ® for gas), home remedies (such as juice for constipation), herbal&#xD;
             preparations, or rehydration fluids that might affect GI tolerance&#xD;
&#xD;
          -  Participant participates in another study that has not been approved as a concomitant&#xD;
             study&#xD;
&#xD;
          -  Participant has been fed a formula containing greater than two HMOs prior to study&#xD;
             enrollment&#xD;
&#xD;
          -  Participant has been fed an extensively hydrolyzed, amino acid based, or preterm&#xD;
             formula prior to enrollment&#xD;
&#xD;
          -  Participant has been fed a formula containing probiotics prior to study enrollment&#xD;
&#xD;
          -  Participant has been fed dietary supplements containing HMO(s), prebiotic(s), or&#xD;
             probiotic(s) prior to study enrollment&#xD;
&#xD;
          -  Participant has an allergy or intolerance to any ingredient in the study product&#xD;
&#xD;
          -  Participant has been treated with antibiotics within 7 days prior to enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>42 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Lasekan, PhD, MS, MBA, CCRP</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott Nutrition</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristen DeLuca, MS, RDN, LDN</last_name>
    <phone>614-624-5455</phone>
    <email>kristen.deluca@abbott.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southeastern Pediatric Associates</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASCLEPES Research Centers</name>
      <address>
        <city>Spring Hill</city>
        <state>Florida</state>
        <zip>34609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Prime</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leavitt Clinical Research</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alivation Research</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ClinOhio Research Services</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dayton Clinical Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Clinical Research</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Coastal Pediatric Research</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midsouth Center for Clinical Research</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DCOL Center for Clinical Research</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clear Lake Specialties</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

